The National Medicines Policy review has accomplished what is a very rare feat

February 11, 2022 Latest News BioPharma Comment

This is a preview of subscriber content

Subscribe now to continue reading.

The review's advisory panel, Deloitte and supporting officials, have certainly achieved something remarkable in being able to unite stakeholder groups that are rarely able to work together. …

Subscribe now to continue reading.

Latest Video

Patient alarm over the potential loss of subsidised access to MS medicines
July 1, 2026 - Latest News
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - Latest News
The minister is following a tried and tested process, but what is the risk in this new world?
July 1, 2026 - Latest News
Major new survey shows patients paying more and waiting longer for medicines
July 1, 2026 - Latest News
Listing delivers access to targeted therapy for Australians living with myasthenia gravis
July 1, 2026 - Latest News

The National Medicines Policy review has accomplished what is a very rare feat

This is a preview of subscriber content

Latest Video

Most Read

Patient alarm over the potential loss of subsidised access to MS medicines

Minister looks to be sending a very clear message about these therapies and the PBS

The minister is following a tried and tested process, but what is the risk in this new world?

Major new survey shows patients paying more and waiting longer for medicines

Listing delivers access to targeted therapy for Australians living with myasthenia gravis

New Stories

Medicines Australia chief says next negotiation is about getting comfortable with being uncomfortable

New once weekly therapy offers extended protection for people with haemophilia A

Nurse prescribing reform set to expand access to PBS subsidised medicines

Nothing else grows below this self-serving and broken institutional framework

Minister looks to be sending a very clear message about these therapies and the PBS

Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy

The end-game of strong-arming companies over prices at the expense of patients and process

Sign In

The National Medicines Policy review has accomplished what is a very rare feat

This is a preview of subscriber content

Latest Video

Most Read

Patient alarm over the potential loss of subsidised access to MS medicines

Minister looks to be sending a very clear message about these therapies and the PBS

The minister is following a tried and tested process, but what is the risk in this new world?

Major new survey shows patients paying more and waiting longer for medicines

Listing delivers access to targeted therapy for Australians living with myasthenia gravis

Follow Us

New Stories

Medicines Australia chief says next negotiation is about getting comfortable with being uncomfortable

New once weekly therapy offers extended protection for people with haemophilia A

Nurse prescribing reform set to expand access to PBS subsidised medicines

Nothing else grows below this self-serving and broken institutional framework

Minister looks to be sending a very clear message about these therapies and the PBS

Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy

The end-game of strong-arming companies over prices at the expense of patients and process